Insmed adds Paul Hudson and Utpal Koppikar to board of directors

Insmed Incorporated announced on October 20, 2026 that its Board of Directors had appointed Paul Hudson and Utpal Koppikar as independent directors. The Board approved the appointments on October 16, 2026, effective October 19, 2026.¹ Hudson was named a Class II director and Koppikar a Class I director, with both subject to election at the company's 2027 Annual Meeting of Shareholders.¹ Hudson joins the Board's Compensation Committee, while Koppikar joins the Audit Committee.¹

Hudson most recently served as Chief Executive Officer of Sanofi S.A. from September 2019 through February 2026, and before that served as CEO of Novartis Pharmaceuticals from 2016 to 2019 and as a member of the Novartis Executive Committee.¹ Earlier in his career, he held senior operational and commercial leadership roles at AstraZeneca, including President of AstraZeneca United States, and began his career in sales and marketing positions at Schering-Plough, GlaxoSmithKline UK, and Sanofi-Synthélabo UK.¹

Koppikar has served as CFO of Verily Health Inc. since April 2023, after serving as Executive Vice President and CFO at Atara Biotherapeutics from 2018 to 2023, and previously held finance leadership roles at Gilead Sciences and Amgen.¹ He currently serves on the Board of Directors of C4 Therapeutics, Inc. (Nasdaq: CCCC).¹

Under the compensation terms disclosed in the filing, each director will receive an annual cash retainer of $65,000, prorated for 2026 based on appointment date.¹ Hudson will receive an additional $12,500 annual retainer for Compensation Committee service, and Koppikar an additional $12,500 for Audit Committee service, both prorated.¹ Each will also receive restricted stock units valued at approximately $585,000 at grant, vesting in equal installments over three years contingent on continued board service.¹

Insmed stated there is no arrangement under which either director was selected, and neither has a material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K.¹